Lilly has initiated two Phase 3 clinical trials, which include 114 domestic obese patients

Photo = Gattyimagesbank. Lilly has initiated two Phase 3 clinical trials, which include 114 domestic obese patients, signaling a competitive landscape with Novo Nordisk and Hanmi Pharmaceutical in the development of obesity treatments. While being a latecomer in the GLP-1 field, Lilly is attracting attention by undertaking large-scale clinical trials targeting both obese individuals with and without diabetes. The oral administration aspect of their treatment is noteworthy in a market already pop

1 trillion KRW club, including Samsung Biologics and Hanmi, achieved their highest first-half sales ever

Photo = Gattyimagesbank. Last year, several members of the 1 trillion KRW club, including Samsung Biologics and Hanmi Pharmaceutical, achieved their highest first-half sales ever. However, Green Cross faced losses due to factors such as increased R&D expenses. Despite the COVID-19 pandemic, there is a clear growth trend in specialized pharmaceuticals. Certain pharmaceutical companies have shown improved performance, yet some still experience deficits due to increased investments in research and

The success of insomnia digital therapy devices depends on the usability by both doctors and patients

Kim Seok-ju, Chairman of the Korean Academy of Sleep Medicine, stated, “The success of insomnia digital therapy devices depends on the usability by both doctors and patients." [Interview] "If the first and second products do not succeed, the subsequent products will also face uncertainties. Success cases are crucial." [관련기사=김석주 수면의학회 이사장 “불면증 디지털 치료기기, 성공 여부는 의사와 환자의 사용성”] Two digital therapeutic devices for cognitive-behavioral therapy for insomnia received approvals in February and April this

The President of the World Sleep Society dreams of a society where the diagnosis, treatment, and management of sleep disorders

[관련기사=세계수면학회장 "수면질환의 진단과 치료, 관리의 보편적 접근성이 보장되는 사회 꿈꾼다"] The President of the World Sleep Society dreams of a society where the diagnosis, treatment, and management of sleep disorders are universally accessible. [Interview] President Raffaele Ferri who visited the Korean Society of Sleep Research discusses the challenges in expanding accessibility to devices such as positive airway pressure machines. He emphasizes that generating clinical evidence regarding digital devices is crucial. Raffaele Fe

Doctors Express Concerns about Participating in Jamboree Competition for Global Youths

"Doctors express concerns about participating in Jamboree competition for global youths - 'There will be casualties if we proceed as Is' Medical teams from Jeonbuk, including the Korean Medical Association and hospitals, were dispatched to provide medical support, but the on-site medical assistance situation remains inadequate. [관련기사=잼버리대회 참여한 세계 청소년들 걱정하는 의사들 "이대로 강행하면 희생자 나온다"] [MedigateNews] Amidst the World Scout Jamboree, which is taking place in SaeManGeum, Jeonbuk's Buan County, from the

Leclaza approved as first-line treatment

[관련기사 = 렉라자 1차치료제 승인 이유? "L858R 변이·뇌전이·아시안·한국인에서 효능 강점"] "Strengths in L858R mutation · brain metastases · Asians and Koreans " Yuhan Corporation’s Leclaza tab(ingredient: Lazertinib) was recently approved by the Ministry of Food and Drug Safety as a first-line treatment for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. The basis for this expansion of approval is the phase 3 clinical trial of LASER301. The LASER301 clinical trial was done in 96 institution

Dong-A ST Blockbuster NASH, obesity treatment in development

[관련 기사 = 동아ST 블록버스터 가능성 주목…경구용 NASH·식욕억제+운동효과 비만주사 개발 중] Kim Mi-Kyung Head of a R&D department says "Obesity drug with oral NASH and appetite suppressant + exercise effect at the same time" Mi-Kyung Kim, head of the Dong-A ST Research Headquarters' Immune Disease Research Division, said in an interview that the company will commercialize DA-1241, a new drug candidate for an oral NASH treatment, and DA-1726, an obesity treatment injection candidate, by 2030. In 2011, Dong-A ST developed DA-1241 a

GE Healthcare worker dies after being crushed by CT table while repairing equipment at hospital

Gettyimage GE Healthcare worker dies after being crushed by CT table while repairing equipment at hospital The Ministry of Employment and Labor investigates on the potential violation against Serious Accident Punishment Act of the company...Emergency of hospital and medical equipment industry [관련기사=GE헬스케어 직원, 병원서 장비 수리 중 CT테이블에 깔려 숨져] [MedigateNews] It is known that an accident occurred in which a GE Healthcare Korea employee was crushed by a CT table while checking a computed tomography (CT) sc

IlDong Pharmaceutical's Unprecedented Large-Scale Restructuring

[관련 기사 = 1분기 실적 엇갈린 명암…일동제약 이례적인 대규모 구조조정] Mixed Results for Mid-Sized Pharmaceutical Companies in the First Quarter... IlDong Pharmaceutical's Unprecedented Large-Scale Restructuring Boryung Seeks New Business Expansion with Strong Growth Momentum, including Aerospace Medicine... SK Bioscience Expands R&D despite Losses due to the ending of Pandemic There is a growing focus on IlDong Pharmaceutical, a domestic mid-sized pharmaceutical company, as it embarks on intense management transformation

'Preventing the disclosure of doctors' identities in the event of expenditure report

Kang Han-cheol, Attorney at Law, from Kim & Chang. [관련 기사 = "의사 실명공개 반대…합법적 경제적이익도 '불법 리베이트' 인식 가능"] "Preventing the disclosure of doctors' identities in the event of expenditure report disclosure and strengthening supervision of CSOs" Both the pharmaceutical industry and the medical and legal sectors have expressed concerns about defamation, loss of trust in doctors, and the activation of illicit rebates. With the impending implementation of the expenditure report disclosure system, criticisms